2025-06-12-花旗集团-辉瑞（PFE）_辉瑞（PFE.N）_前景广阔的乳腺癌产品线亮点_11页_304kb

Key Focus

Pfizer (PFE.N) presented a strong breast cancer pipeline in its latest report. The focus is on developing innovative therapies to maintain market competitiveness amid the loss of exclusivity for Ibrance in 2027.

Pipeline Overview

1. Key Drugs:

   • Atirmociclib: A selective CDK4 inhibitor designed for frontline and early breast cancer treatment, with better tolerability than existing inhibitors.
   • Vepdegestrant: A PROTAC-based estrogen receptor degrader; Phase 3 trial (VERITAC-2) showed improved PFS in ESR1-mutant patients. Submitted NDA for FDA approval.
   • KAT6 Inhibitor: Targets later-line therapy to overcome resistance to endocrine and CDK4/6 treatments; Phase 1 showed 37.2% ORR in ER+ HER2- metastatic cancer.
   • CDK2 Inhibitor: Designed to overcome resistance to CDK4/6 inhibitors.
   • Disitamab Vedotin (DV): HER2-targeted ADC being evaluated for triple-negative breast cancer.

2. Combination Strategies:

   • Pfizer is exploring combinations with vepdegestrant and potentially with its own partners for broader efficacy.
   • Early results from atirmociclib Phase 3 trial are pending.

Valuation

• Target Price: $25 per share (DCF-based, WACC 8%, terminal growth 1%).
• Risks: Pipeline disappointments, Ibrance sales below forecasts, competition from Padcev, and M&A dilution.
• Upside Catalysts: Strong ADC sales, clinical trial successes, and growth product uptake.

Analyst Takeaway

Pfizer's advancements position it to compete in breast cancer with atirmociclib as a potential backbone therapy, but some risks remain to reach the target price. Maintain Neutral rating.